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Abstract
The spikes of the human immunodeficiency virus (HIV) mediate viral
entry and are the most important targets for neutralizing antibodies. Each
spike consists of three identical subunits. The role of the spike’s subunits
in antibody binding is not fully understood. One experimental approach to
analyze trimer function are assays with mixed envelope trimer expressing cells
or viruses. As these experiments do not allow direct observation of subunit
functions, mathematical models are required to interpret them. Here we
describe a modeling framework to study (i) the interaction of the V1V2 loop
with epitopes on the V3 loop and (ii) the composition of quaternary epitopes.
In a first step we identify which trimers can form in these assays and how
they function under antibody binding. We then derive the behavior of an
average trimer. We contrast two experimental reporting systems and list
their advantages and disadvantages. In these experiments trimer formation
might not be perfectly random and we show how these effects can be tested.
∗corresponding author
Email address: magnus.carsten@virology.uzh.ch (Carsten Magnus)
Preprint submitted to Journal of Immunological Methods February 18, 2014
As we still lack a potent vaccine against HIV, and this vaccine surely has to
stimulate the production of neutralizing antibodies, mixed trimer approaches
in combination with mathematical models will help to identify vulnerable
sites of the HIV spike.
Keywords: human immunodeficiency virus envelope interactions, epitope
masking by variable loops 1 and 2, quaternary epitopes, mathematical
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1. Introduction1
HIV-1 enters target cells by virtue of its envelope glycoprotein spikes in-2
corporated into the viral membrane [17, 80]. Envelope glycoproteins (Env)3
form heterodimers (in structural context referred to as protomer), comprising4
a gp120 subunit non-covalently linked to the transmembrane subunit gp415
and assemble as trimers to form the functional spike [59, 75, 84]. Binding of6
envelope-specific antibodies to the envelope trimer interferes with the entry7
process and results in virus neutralization [4, 35]. Eliciting neutralizing an-8
tibodies to HIV is considered a crucial function of an effective HIV vaccine9
[3, 23, 48, 71]. However, despite a vigorous antibody response directed to10
the HIV envelope proteins, potent and broadly neutralizing antibodies are11
scarce [15]. A number of factors account for this, foremost the architecture of12
the viral envelope spike, which restricts binding of antibodies to vulnerable13
sites on the envelope trimer. The trimeric arrangement of the protomers,14
an extensive and variable glycan shield, protection of receptor-binding sites15
by conformational masking, and variable loops that shield distant epitopes16
within the trimer all act in synergy to protect the envelope proteins from17
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antibody attack [5, 8, 34, 36, 45, 62, 65, 77, 82].18
The variable loops 1 and 2 (V1V2) play a dominant role in shielding the19
envelope trimer against neutralizing antibodies [6, 32, 51, 55, 66, 83]. A20
marked increase in sensitivity to antibodies directed against the V3 loop,21
the CD4-binding site and CD4-induced epitopes can be observed upon the22
introduction of certain mutations within V1V2, or upon deletion of the entire23
V1V2 domain [7, 16, 26, 38, 41, 42, 52, 56, 63, 68, 70, 81, 90]. V1V2 also24
appears to be involved in the entry process [6, 20, 30, 31, 53, 54, 61, 69, 72–25
74, 85]. During the course of the infection, HIV undergoes a substantial26
sequence evolution within each infected individual. Over time the evolving27
viral quasipecies portray a high sequence variability in the V1V2 domain,28
including length polymorphisms and variable glycosylation patterns, likely29
reflecting both direct antibody pressure on V1V2 as well as the need to adapt30
its shielding to antibodies directed against distal epitopes [1, 9, 10, 14, 18,31
21, 25, 37, 39, 58, 63]. A similar effect has been reported on the population32
level, where the length and number of glycosylation sites of V1V2 have been33
suggested to have increased over the course of the HIV-1 pandemic [2, 11].34
To date, no crystal structure of the V1V2 domain in the context of gp12035
has been obtained, thus detailed, atomic level information of the structure36
and position of the V1V2 domain in the context of a single gp120 subunit37
both in the monomeric state and in the assembled trimer are missing [33].38
Cryo-electron microscopy (cryo-EM) studies provide strong evidence that39
V1V2 resides at the apex of the spike, where it interacts with the V3 loop40
[24, 39, 47, 79]. Recent studies reported a structure of the spike at high41
resolution, allowing the discrimination of individual domains within gp120,42
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and identified the interaction between V1V2 and V3 at the spike apex as the43
major trimer association domain between individual gp120 subunits [46, 47].44
In recent years, cryo-EM reconstructions have proven valuable in study-45
ing and understanding global interactions between Env trimers and neu-46
tralizing antibodies. However, these techniques do not provide atomic level47
resolution and therefore cannot resolve functional details on the HIV entry48
process nor on the modes of trimer interaction with antibodies. One experi-49
mental approach that has proven useful in studying such complex processes50
and interactions is based on the production and analysis of mixed envelope51
trimers, i.e. trimers consisting of envelope subunits which differ in sequence52
and functionality. Mixed trimers are generated by co-transfection of suit-53
able cells with the respective envelope encoding plasmids, resulting in either54
cells or pseudotyped virions displaying mixed trimers on their surface. These55
mixed trimer expressing cells or virions can be utilized in antibody bind-56
ing studies, neutralization or entry assays. Complicated stochastic effects57
during trimer formation and expression as well as during entry, antibody58
binding and neutralization makes it necessary to analyze the resulting data59
with mathematical models as we previously demonstrated [43–45, 62]. Mixed60
trimer approaches have been used to study the stoichiometries of the HIV61
entry process, namely the number of trimers needed for entry [28, 45, 87]62
(stoichiometry of entry, denoted by T ), the number of antibodies needed to63
neutralize a trimer [28, 43, 67, 86] (stoichiometry of trimer neutralization,64
denoted by N) , the number of required functional subunits within a trimer65
[44, 88] (subunit stoichiometry, denoted by S or σ), the effect of comple-66
mentation between protomers within the trimer [64], and the formation of67
4
quaternary epitopes [76].68
We recently utilized a mixed trimer approach to define the interaction69
between V1V2 and V3 with the aim to unravel the molecular basis for the70
potent shielding of V3 by V1V2 [62]. Two different mechanisms can be envi-71
sioned in this context: (i) The V1V2 loop of a given gp120 protomer within72
a trimer interacts with the V3 loop on a neighboring gp120 subunit, and73
thereby shields epitopes located on the neighboring V3 loop from antibody74
binding. This inter-protomeric mode of shielding is referred to as neighboring75
or trans protection. (ii) The V1V2 interacts with the V3 loop that belongs to76
the same gp120 subunit. This intra-protomeric mode of shielding is referred77
to as self or cis protection (see Figure 1 A). By studying antibody binding to78
the mixed trimers expressed on cells with flow cytometry and following anal-79
ysis with mathematical models, we concluded inter-protomeric (i.e. neigh-80
boring or trans) shielding of the V3 loop by the V1V2 domain. However,81
another study, employing a mixed trimer approach based on an infectivity82
readout without detailed mathematical analysis, came to the opposite con-83
clusion, namely intra-protomeric (i.e. self or cis) interaction of V1V2 with the84
V3 loop [40]. Based on our current understanding both observations could85
potentially be correct. This might be the case if the V1V2 can adopt more86
than one conformation on the intact trimer or if the V1V2 conformation is87
strain dependent. Further, based on the trimer structure described by Mao88
et al. [46, 47] it remains possible that the V1V2 domains contacts V3 loops89
both from its own and a neighboring subunit at the spike apex.90
The interaction between V1V2 and V3 is of relevance not only for an-91
tibody shielding, but it also constitutes epitopes that can be recognized by92
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neutralizing antibodies. In many cases these epitopes appear to be preferen-93
tially formed on intact trimers and not on soluble gp120 molecules and are94
referred to as quaternary epitopes. Several antibodies recognizing quaternary95
epitopes depending on both V1V2 and V3 have been isolated, including the96
broad and potent antibodies PG9 and PG16 [19, 60, 76]. Recently, co-crystal97
structures of the V1V2 loop with PG9 were used to identify interaction sites98
in this complex at an atomic level [49]. However, this approach does not clar-99
ify why theses antibodies preferentially bind to trimers and not to monomeric100
gp120. [27] combined electron microscopy, small angle X-ray scattering, size101
exclusion chromatography with inline multiangle light scattering and isother-102
mal titration calorimetry to demonstrate that one PG9 binds per trimer by103
making contact between one PG9-Fab region and two of the three protomers104
of an artificially stabilized gp140 trimer. In analogy to the analyses employed105
to define the mode of V3 shielding by V1V2, experiments relying on mixed106
trimers can be employed to test whether quaternary epitopes are formed107
by intra-protomer (non-shared epitopes, no cross-linking) or inter-protomer108
(shared, cross-linking) interactions within the intact trimer (see Figure 1B).109
The experimental basis of mixed trimer formation appear to be simple.110
The co-transfection of two envelope protein encoding plasmids at specific ra-111
tios seem to lead to the formation of mixed trimers reflecting these ratios.112
However, a multitude of random processes can occur during mixed trimer113
formation which can lead to differential expression profiles [43, 45]. A verifi-114
cation that trimer formation occurs at the desired molecular ratios is complex115
and requires both experimental analysis and employment of mathematical116
models to interpret data obtained from any such experimental system.117
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In the following, we describe and compare the two main approaches that118
have been used to answer specific questions about HIV envelope trimer func-119
tion during entry and its inhibition by antibodies. In the recent literature,120
two experimental system have been employed for these types of questions.121
Here, we review these approaches and the corresponding models to reveal122
the advantages and disadvantages of either framework.123
In particular, we address three major issues about these approaches: (i)124
Searching for the optimal experimental setup: Which experimental approach125
based on mixed trimer analysis is suited best to address molecular interac-126
tions of trimer protomers and antibodies? (ii) Deviation from the “ideally127
mixed” trimer: Several factors potentially influence the assembly of mixed128
trimers [43, 45]. We outline in detail how our model framework can be em-129
ployed to test the effect of different assumptions concerning trimer formation130
on the predictions of experimental outcomes. (iii) We further demonstrate131
how our framework can be extended to study the contribution of individual132
envelope glycoproteins to the formation of quaternary epitopes (see Figure133
1 B). These approaches make it possible to verify and define quaternary HIV134
Env specific antibodies and in particular to define whether epitopes of these135
antibodies are shared between neighboring protomers or originate from one136
protomer within the trimer.137
2. Materials and Methods138
In this section we describe the general experimental setup to study enve-139
lope trimer functions in the context of antibody binding and neutralization.140
In our approach each trimer species is displayed in a trimer table and rated141
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for functionality. Type, frequency and functionality of the trimer species142
are then translated into mathematical equations to predict the outcome of143
a certain experimental setup. These predictions indicate which experimen-144
tal setups can be used to gain insights into specific aspects of inter- and145
intra-protomeric envelope functions.146
2.1. Experiments147
In principle two types of experimental approaches can be used to study148
inter- and intra-trimeric functions in the context of antibody binding and149
neutralization. In the first approach, antibody binding to mixed trimers150
expressed on transfected cells can be analyzed by flow cytometry. We refer151
to this approach in the following simply as binding assays (see also Figure152
2 A). In the second approach, infectivity of pseudotyped virions expressing153
mixed trimers is evaluated in presence and absence of neutralizing antibodies.154
We refer to this experimental approach in the remainder of our study as155
infectivity assays (see also Figure 2 B).156
In both experimental approaches mixed trimers are generated by co-157
transfecting suitable human cell lines with two different plasmids each en-158
coding for another envelope variant [12, 67, 86–88]. For a typical experiment,159
a range of separate transfection reactions will be performed in parallel with160
varying the ratios of one envelope variant to the other. A central assumption161
of these experiments is that both plasmids enter the cells equally efficiently162
and are transcribed and translated at the same rate, such that the produc-163
tion of both envelope variants within the cells is reflected by the ratio of164
the transfected plasmids. Further, it is assumed that both envelope variants165
trimerize perfectly randomly, such that the proportions of the different homo-166
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and heterotrimers displayed on the transfected cell or the pseudotyped virion167
can again be predicted by the ratio of transfected envelope plasmids.168
For binding assays, cells are transfected with the envelope plasmids only,169
which results in expression of envelope trimers on the cell surface. Domains170
or epitopes of interest on these mixed trimers can then be analyzed by flow171
cytometry utilizing fluorescently labeled Env specific antibodies (see Figure 2172
A). It is assumed that the measured fluorescence intensity of a cell population173
is directly correlated with the availability of epitopes on the trimers that the174
respective antibodies are directed to. The mean fluorescence intensity, MFI,175
of a cell population expressing mixed trimers is obtained by subtracting the176
mean of the background signal (obtained from mock-transfected cells) from177
the mean of the cellular signal of the population expressing mixed trimers178
(for a schematic see Figure 3). Of note, Env proteins on transfected cells179
and virions are known to build intact trimers but also partially shed spikes,180
containing only one or two gp120 proteins. As in these incomplete spikes181
antibodies might also have access to epitopes that are not accessible in the182
intact trimers, the MFI must be corrected for this additional binding.183
For the infectivity assays, pseudotyped virus is produced by addition-184
ally co-transfecting an env-deleted HIV proviral plasmid which results in185
the production of single-round infection competent, envelope pseudotyped186
virus (pseudovirus). For infectivity assays, the generated pseudotype virus187
stocks expressing different ratios of mixed trimers are subjected to saturating188
antibody concentrations and their capability to infect a target cell line is de-189
termined. In essence any susceptible target cell can be used in these studies190
and HIV infection monitored by various means e.g. HIV antigen production,191
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viral RNA quantification, or reporter gene expression. A convenient and192
often used target cell line for HIV neutralization assays are TZM-bL cells,193
which express firefly luciferase upon HIV infection and thus allow rapid and194
quantitative monitoring of HIV infectivity [50, 78]. Figure 2 outlines the ba-195
sic features of the two setups. Binding assays were performed in [62] whereas196
infectivity assays were performed in [40] to study the mode of protection the197
V1V2-loop confers.198
2.2. Analysis of trimer functionality using trimer tables199
To study inter- and intra-protomeric functions in the context of antibody200
binding and neutralization, mixed trimers are used in experimental setups as201
described above. The two envelope proteins used must vary in their specific202
characteristics, such as presence or absence of a given epitope or of variable203
loops. Let us first consider an analysis of the mode of interaction between204
the V1V2 and V3 loops, i.e. dissection of neighboring (trans) or self (cis)205
interaction. To address this question, the envelope subunits in the mixed206
trimers must have different features: the V1V2 loop must either be present207
or deleted and the antibody binding site must either be antibody binding208
sensitive or defective. In more theoretical terms this means that there is a209
locus a in the envelope protein with two different variants a1 and a2 and210
another locus b with two variants b1 and b2. For example, locus a1 can be en-211
gineered to delete the envelope V1V2 while locus a2 carries the intact V1V2212
domain. In analogy, the envelope variant b1 encodes for a mutation in V3213
rendering this protomer resistant to antibody binding while b2 encodes for214
the antibody sensitive wild-type. Since there are two loci with two different215
variants each, there are 22 = 4 possible envelope protein combinations. For216
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generating mixed trimers, two envelope proteins out of the four possible com-217
binations are chosen for an experimental setup. Thus there are theoretically218 (
4
2
)
= 6 possible experimental setups.219
However, not all theoretically possible experimental setups contain the in-220
formation necessary to distinguish between own or neighboring interaction.221
An easy tool to decide whether an experimental setup contains enough in-222
formation to distinguish the different scenarios is a trimer table as presented223
in Figure 4. A trimer table lists all the different mixed trimers that can be224
formed in one specific experimental setup and also includes the antibodies225
bound depending on the different hypotheses to test. If there is at least one226
trimer which differs in its functions depending on the hypotheses that shall227
be tested, the setup can be used to test these hypotheses. There are only228
two out of the six theoretical envelope combinations fulfilling this condition229
for our example of the V1V2-V3 interaction.230
Figure 4 contrasts trimer tables for binding assays with those for infectiv-231
ity assays in three theoretically possible setups. Setup I and II can be used232
to infer the mode of interaction between V1V2 and V3, whereas setup III233
cannot be used for this purpose. This is because the different trimers in setup234
III have the same functionality for the two different interaction hypotheses,235
i.e. the trimer tables are identical for both hypothesis. Which of the two236
assays, binding or infectivity, is more suitable is discussed below.237
Trimer tables can also help in other experimental setups. To dissect238
whether quaternary epitopes are constituted of components belonging to239
neighboring envelope proteins within the trimer, an experimental setup in-240
cluding envelope variants with defects in the epitopes must be used. An241
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example of a trimer table reflecting this situation can be found in Figure 9 B.242
2.3. Models243
The trimer tables must be transformed into mathematical formula to244
predict the behavior of different trimer combinations under different hypo-245
thetical assumptions. As the exact number of trimers expressed on a single246
transfected cell or on an individual pseudotyped virion is not known and247
cannot be precisely determined, the conducted experiments will only inform248
about trimer functionality and virion infectivity averaged over all trimers and249
virions of a population, respectively. Therefore, it is necessary to perform250
experiments with different envelope variant ratios and assess the qualitative251
change of the average number of antibodies bound in binding assays or the252
relative infectivity in infectivity assays, respectively.253
In this section we describe the general assumptions of the models. We254
then derive the probability to form a trimer with a specified envelope compo-255
sition. This probability forms the basis of models for binding and infectivity256
assays. In the section “Infectivity assays” we derive the relative infectivity257
measured in infectivity assays. The relative infectivity measures how well a258
virus stock expressing mixed trimers infects target cells under saturation of259
antibodies in comparison to the stock in absence of antibodies. In the sec-260
tion “Binding assays” we derive the normalized mean fluorescence intensities261
measured in binding assays. This measure informs about the average number262
of antibodies bound to cells expressing mixed trimers. In the sections “Con-263
sidering imperfect transfection” and “Considering envelope segregation” we264
derive models under relaxed assumptions concerning trimer formation.265
The models presented here are built on the following assumptions:266
12
1. A sufficiently high number of envelope encoding plasmids enters the267
transfectable cell. This guarantees that the plasmids inside the cell268
have the same relative composition as outside, adjusted at the begin-269
ning of the transfection. This assumption is relaxed in the imperfect270
transfection model.271
2. Plasmids are translated into proteins and trimers are formed from the272
envelope protein pool within the cell.273
3. Three envelope proteins are chosen perfectly randomly to build a trimer274
out of the envelope pool. This assumption is relaxed in the segregation275
model.276
In a system with two different envelope proteins A and B, we denote the277
fraction of envelope encoding plasmid with fA and fB = 1− fA, respectively.278
Under the above assumption the number of envelope proteins of type A279
follows a binomial distribution with parameters 3 and fA, i.e. the probability280
that k = 0, 1, 2, 3 envelope proteins within one trimer are of type A is281 (
3
k
)
fkA(1− fA)3−k (1)
All parameters used are listed in table 1.282
2.3.1. Infectivity assays283
For infectivity assays we can predict the relative infectivity of pseudo-284
typed virus stocks in the presence of monoclonal antibodies. Following the285
concept of stoichiometries, a virion is only able to infect a cell when at least286
T functional trimers attach to cell receptors. A trimer is functional when287
less than N antibodies are bound to the trimer [28, 29, 43, 45, 67, 86, 87].288
Virions vary in trimer expression and the fraction of virions that express s289
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trimers is ηs for s = 0, 1, . . . , smax. For all predictions of the relative infectiv-290
ity in infectivity assays we use smax = 100 and a discretized beta-distribution291
with mean 14 and variance 49. This distribution is based on trimer number292
counts on HIV-1 virions [91], and details of its definition are laid out in [45].293
Let fA be the fraction of envelope encoding plasmids with binding sensitive294
epitopes. The relative infectivity for a binding scenario S can then be derived295
according to [43, 45]296
RI(S, T,N, η, fA) =
∑smax
s=T ηs
(∑s
g=T
(
s
g
)
αS,N
g(1− αS,N)(s−g)
)
∑smax
k=T ηk
(2)
where αS,N is the probability that a functional trimer forms given the sto-
ichiometry of neutralization N and the scenario S. This can be calculated
by summing over the probabilities to form a functional trimer with k type A
envelope proteins (equation 1). As an example of how αS,N can be calculated
we look at infectivity assays in setup I (first row, second column in figure 4).
All trimers are functional (indicated by ”+”) except the heterotrimers in the
neighboring scenario assuming that one antibody is enough to neutralize a
trimer (i.e. N = 1). The probability that a functional trimer forms under
these assumptions is the sum of forming homotrimers. Applying equation 1,
we obtain
αneigh,1 =
(
3
0
)
f 0A(1− fA)3−0 +
(
3
3
)
f 3A(1− fA)3−3 = (1− fA)3 + f 3A
where type A envelope proteins are antibody binding sensitive and have the297
V1V2 loop.298
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2.3.2. Binding assays299
For binding assays we predict the normalized mean fluorescence intensity300
for a series of cell populations expressing mixed trimers. Each cell population301
is produced with a certain fraction of type A encoding plasmids. We obtain302
a curve of the normalized mean fluorescence intensity as a function of the303
fraction of type A envelope proteins. To derive this curve, we first define X as304
the number of antibodies binding to one random trimer. The mean number305
of antibodies binding to one trimer given the fraction of type A envelope306
proteins, fA, is then:307
EX =
3∑
k=0
nkP (X = k) =
3∑
k=0
nk
(
3
k
)
fkA(1− fA)3−k (3)
where nk denotes the number of antibodies that bind to a trimer with k type308
A envelope proteins, for k = 0, . . . , 3. The normalized mean fluorescence309
intensity, nMFI, is a function in fA and n := (n0, n1, n2, n3):310
nMFI(n, fA) =
1
max
x∈[0,1]
{∑3k=0 nk(3k)xk(1− x)3−k}
3∑
k=0
nk
(
3
k
)
fkA(1− fA)3−k
(4)
where n must be determined via the trimer tables and thus depends on311
the particular hypothetical scenario. For example, in binding assays and312
setup I (first row, first column in figure 4) n = (0, 1, 1, 0) in the neighboring313
protection scenario and n = (0, 0, 0, 0) in the self protection scenario.314
2.3.3. Considering imperfect transfection315
In the models described above we assumed that the fraction of type A316
envelope proteins in the envelope pool is equal to the fraction of type A317
encoding plasmids that were transfected. If only a few plasmids can enter318
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the cell or the expression of one plasmid is favored over the other, the frac-319
tion of type A envelope proteins in the envelope pool differs from fA. We320
extend the basic model to allow imperfect transfection, or more general varia-321
tion between the envelope pool and the plasmid ratios [43, 45]. We described322
models considering imperfect transfection in the context of the stoichiometry323
of entry and neutralization [43, 45] and in the context of V1V2 loop protec-324
tion [62] earlier. Here we show how the mean fluorescence intensity and the325
normalized mean fluorescence intensity can be derived in these model ex-326
tensions and which additional information can be obtained by studying the327
(non-normalized) mean fluorescence intensity.328
We model the fraction of type A envelope proteins in the envelope pool329
as a B-distributed random variable FA with mean fA ∈ (0, 1) and variance330
v = v˜fA(1− fA) (5)
where v˜ ∈ (0, 1) denotes the coefficient of variation.331
In the models for infectivity assays, the probability that a functional332
trimer forms, αS,N , in equation 2 has to be adapted. Trimerization is again333
assumed to be binomial but now with the distribution B(3, FA). Thus, the334
probability that an average trimer has k = 0, 1, 2, 3 type A envelope proteins335
is336 ∫ 1
0
(
3
k
)
xk(1− x)3−kβfA,v˜(x)dx (6)
βfA,v˜ is the probability density function of a B-distribution with mean fA337
and coefficient of variation v˜ which is equivalent to a B-distribution with338
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parameters p and q, given the definitions339
p :=
f 2A − f 3A − v˜f 2A(1− fA)
v˜fA(1− fA)
q :=
fA − 2f 2A + f 3A − v˜fA(1− fA) + v˜f 2A(1− fA)
v˜fA(1− fA) (7)
This equivalence holds because the B-distribution with parameters p and q340
has mean p
p+q
and variance pq
(p+q+1)(p+q)2
. Hence341
RIitm(S, T,N, η, fA, v˜) =
∑smax
s=T ηs
(∑s
g=T
(
s
g
)
αitmS,N
g
(1− αitmS,N)(s−g)
)
∑smax
k=T ηk
(8)
where αitmS,N is the probability that a trimer is functional given the scenario342
S and the stoichiometry of neutralization N .343
In binding assays, we replace the fraction of type A envelope proteins,344
fA, in equation 4 by the random variable FA. By taking the mean, we obtain345
for the normalized mean fluorescence intensity in the imperfect transfection346
model:347
nMFIitm(n, fA) =
1
max
x∈[0,1]
gitm(n, x, v˜)
gitm(n, x, v˜) (9)
with348
gitm(n, x, v˜) = E
(
3∑
k=0
nk
(
3
k
)
F kA(1− FA)3−k
)
(10)
Because EXn = (EX)n only if V arX = 0, imperfect transfection will have an349
influence on the predictions for the normalized mean fluorescence intensity.350
However, this influence decreases when the coefficient of variation goes to 1351
(which also implies that the variance of FA goes to 1).352
In addition to the normalized mean fluorescence intensity, the (non-353
normalized) mean fluorescence intensity adds to the understanding of po-354
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tential imperfect transmission. The (non-normalized) mean fluorescence in-355
tensity is the same as gitm(n, x, v˜) shown in equation 10. For a coefficient356
of variation close to 1, almost every cell is transfected with only one type of357
envelope encoding plasmid. Hence, most of the cells express only one type of358
homotrimers. The few cells that are transfected with two types of envelope359
encoding plasmids have a huge variation in the composition of heterotrimers.360
If imperfect transfection plays a role in the generation of mixed trimers, this361
effect must be reflected in flow cytometry readouts.362
2.3.4. Considering envelope segregation363
During the formation of mixed trimers, it could be possible that ho-364
motrimers are preferentially built. In this case, trimer formation would365
not happen perfectly randomly, i.e. may not follow a binomial distribution366
[43, 45]. In the following, we extend the models for the relative infectivity367
and the mean fluorescence intensity to incorporate this possibility. To this368
end, we introduce a parameter ξ ∈ [0, 1] describing the degree of segregation369
of two envelope variants towards homotrimers. ξ = 0 means that there is370
no segregation and trimer formation occurs according to a binomial distri-371
bution. ξ = 1 describes a scenario in which only homotrimers are formed.372
In the extended model, trimer formation is conceived as the successive ad-373
dition of envelope proteins. The incorporation of an envelope protein of the374
same type as the previous one is more likely than the incorporation of one375
of a different type. If we denote the fraction of type A envelope proteins in376
the envelope pool as fA, the probability of incorporating another envelope of377
type A is f 1−ξA . Thus, the probability that a trimer has three type A envelope378
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proteins is379
P3 = fAf
1−ξ
A f
1−ξ
A = f
3−2ξ
A (11)
Similarly, the probability that an envelope protein of type B is incorporated380
when there is already one of this type in the trimer is defined as (1− fA)1−ξ.381
Thus, the probability that a trimer has three type B proteins, or no type A382
protein, is383
P0 = (1− fA)3−2ξ (12)
The probabilities Pk that a trimer forms with k = 1, 2 type A envelope384
proteins can similarly be derived as:385
P1 = fA
(
1− f 1−ξA
)2
+ 2(1− fA)2−ξ
(
1− (1− fA)1−ξ
)
P2 = (1− fA)
(
1− (1− fA)1−ξ
)2
+ 2f 2−ξA
(
1− f 1−ξA
)
(13)
Equations 11 – 13 define a valid probability distribution, because 0 ≤ Pk ≤ 1386
for k = 0, 1, 2, 3 and the probabilities sum to 1 (see also [43]).387
Replacing the probabilities to form a trimer with k type A envelope pro-388
teins in equation 2 leads to the following prediction of the relative infectivity389
in infectivity assays390
RIseg(S, T,N, η, fA) =
∑smax
s=T ηs
(∑s
g=T
(
s
g
)
αsegS,N
g(1− αsegS,N)(s−g)
)
∑smax
k=T ηk
(14)
where αsegS,N is the probability that a trimer is functional given the scenario S391
and the stoichiometry of neutralization N . This probability can be obtained392
by summing over all probabilities Pk of trimers with k type A envelope pro-393
teins that are functional.394
If we apply this to infectivity assays in setup I (first row, second column395
in figure 4) αsegneigh,1 = P
3
1 + P
3
2 and equals one for the stoichiometries of396
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neutralization N = 2 and N = 3 in the neighboring protection scenario as397
well as for all stoichiometries of neutralization in the self protection scenario.398
Type A envelope proteins are V1V2 deleted and antibody binding resistant399
in this example.400
The mean fluorescence intensity in binding assays for the imperfect trans-401
fection model is similarly derived by replacing the probability that a trimer402
with k type A antibodies forms in equation 4 with the probability Pk derived403
in equations 11 – 13. Thus404
nMFIseg(n, fA) =
1
max{∑3k=0 nkPk}
3∑
k=0
nkPk (15)
The vector n containing the numbers of antibodies that bind to a trimer with405
k type A envelope proteins must be read out of a trimer table.406
With increasing segregation, i.e. ξ → 1, fewer heterotrimers will be407
expressed on the cell surface. If the number of antibodies binding to ho-408
motrimers differs from the number of antibodies binding to hetereotrimers,409
the intensity of the fluorescence signal will change across different cell lines ex-410
pressing different mixtures of envelope proteins. Therefore one can also gain411
insight into the process of segregation by looking at the (non-normalized)412
mean fluorescence intensity:413
MFIseg(n, fA) =
3∑
k=0
nkPk (16)
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3. Results414
3.1. Analysis of protomer interactions within trimers using binding and in-415
fectivity assays416
In Figure 5 we show the theoretical predictions for six different exper-417
imental systems. Each row corresponds to a different combination of two418
envelope proteins. The mixed trimers expressed on envelope plasmid trans-419
fected cells are subjected to an antibody which targets an epitope of interest420
at saturating concentrations and cells are analyzed for antibody binding by421
flow cytometry. The predictions for the normalized mean fluorescence inten-422
sity, nMFI, as a function of the fraction of type A envelope proteins for the423
different binding scenarios is shown in the column “binding assay”. If the424
envelope plasmid transfected cells are additionally transfected with plasmids425
encoding for the viral genome, pseudotyped virions expressing mixed trimers426
are produced. These pseudotype virus stocks are subjected to saturating427
antibody concentrations and their capacity to infect target cells is assayed.428
The predictions for the relative infectivity, i.e. the infectivity of a pseudo-429
typed virus stock reacting with antibodies divided by the infectivity of the430
same virus stock without antibodies, are shown in the column “infectivity431
assays”. For these predictions we assumed a stoichiometry of entry T = 8,432
an estimate we obtained in [45] for the basic model. The predictions shown433
in figure 5 correspond to the trimer tables in figure 4.434
3.1.1. Binding assays435
Predictions for this assay type are shown in the column “binding assays”436
in figure 5 and this paragraph refers to binding assays only. Setup III can be437
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used as a control setup, because the different interaction scenarios between438
V1V2 and V3 are not distinguishable. In setup I and II, the different inter-439
action scenarios are predicted to result in clearly distinguishable normalized440
mean fluorescence intensity curves. If the interaction between V1V2 and441
V3 is inter-protomeric (neighboring/ trans protection), we expect a hump-442
shaped curve for the normalized mean fluorescence intensity as a function of443
the fraction of V1V2 deleted, antibody resistant envelope proteins in setup444
I, compared to a flat line (i.e. no antibody binding to any trimer) for own445
protection. In setup II, we expect a bow-shaped curve for neighboring pro-446
tection, compared to a linear relationship between antibody binding and the447
fraction of V1V2 deleted - antibody sensitive envelope proteins for own pro-448
tection. We previously confirmed these predictions experimentally [62].449
3.1.2. Infectivity assays450
Predictions for this assay type are shown in the column “infectivity as-451
says” in figure 5. This paragraph refers to infectivity assays only. As men-452
tioned above, we assume T = 8 for the predictions in figure 5 in accordance453
with the estimates for the basic model, i.e. the model assuming perfectly454
random trimer formation and no segregation nor imperfect transfection [45].455
The predictions for the different relative infectivities not only depend on the456
hypothesized mode of interaction between V1V2 and V3, but also on stoi-457
chiometric parameters. In setup I, we predict constant relative infectivity of458
100% for self (cis) protection for all stoichiometries of trimer neutralization459
N = 1, 2, 3 but we also predict the same straight line for neighboring (trans)460
protection for N = 2 and N = 3. Only in case N = 1, our model predicts a461
valley-shaped curve for neighboring protection. This means that the mode of462
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V1V2 interaction with V3 can only be inferred with setup I if the monoclonal463
antibody used in the experiments has a (N = 1)-stoichiometry. Infectivity464
assays as shown in setup II also yield ambiguous results. Only if the data fits465
the self protection and (N = 1)-curve, can one deduce self protection and466
N = 1. If the stoichiometry of neutralization is known and is either N = 1 or467
N = 2, the mode of protection can be distinguished according to the relative468
infectivity curves. In addition, the stoichiometry of entry, T , has a strong469
influence on the model predictions in both setups. In setup I the valley is470
the deeper, the higher the entry stoichiometry, T is as we show in figure 6471
(A). In setup II we can see that the higher T is, the more are all relative472
infectivity curves shifted to the left (shown in Figure 6 (B)). Therefore it is473
possible that relative infectivity curves for different parameter sets and mode474
of protections are identical making it impossible to determine the mode of475
V1V2 protection without prior knowledge of stoichiometric parameters.476
In addition to uncertainties related to the stoichiometries of entry and neu-477
tralization, the distribution of the number of trimers across different virions478
has a huge impact on the predictions of the relative infectivity curves, as479
shown in [28, 43, 45]. The more trimers a virion displays on average, the480
more are the relative infectivity curves shifted to the right. The variation in481
the trimer number distribution influences the slope of the relative infectiv-482
ity curves. Neither the stoichiometries of entry and neutralization nor the483
distribution of trimer numbers are conclusively determined yet. Therefore,484
different modes of V1V2 interaction with V3 cannot clearly be distinguished485
in infectivity assays. Binding assays, on the other hand, do not include the486
infection step and therefore all ambiguities associated with this step such487
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as the trimer number distribution on virions as well as the stoichiometry of488
entry and neutralization, do not affect the predicted normalized mean fluo-489
rescence intensity curves. Therefore, we only consider binding assays in the490
following sections.491
3.2. Testing different assumptions concerning trimer formation492
In Figure 7 we show how imperfect transfection and segregation influence493
the predictions for the normalized mean fluorescence intensity for experimen-494
tal setup I (in figure 4). If the transfection of cells with envelope encoding495
plasmids is imperfect, the predictions for the normalized mean fluorescence496
intensity for both modes of V1V2 interaction with V3 are the same as for the497
basic model tested above (figure 7 A). However, if the self protection scenario498
holds true, higher segregation coefficients broaden the normalized mean flu-499
orescence curves for the neighboring protection scenario. The predictions for500
the self protection scenario is not affected by segregation (figure 7 B).501
The normalized mean fluorescence intensity neglects variation in the strength502
of fluorescence signals that might include additional information. The fluo-503
rescence signal in binding assays for neighboring protection in setup I comes504
from antibodies binding to heterotrimers with one or two V1V2 expressing505
and antibody binding sensitive envelope proteins (see Figure 4). Both model506
extensions accounting for imperfect transfection and segregation for the nor-507
malized mean fluorescence intensity (equations 9 and 15) predict a hump508
shaped curve for any coefficient of variation, v˜, and segregation parameter,509
ξ. However, the expression of heterotrimers expressed decreases with in-510
creasing v˜ as well as increasing ξ. This leads to a reduction of the mean511
fluorescence intensity measured with flow cytometry. We predict this effect512
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in figure 8 for the model extensions accounting for imperfect transfection513
(A) and segregation (B). The decrease in MFI signal can be used to study514
potential imperfect transfection or segregation. Here, we demonstrate how515
segregation can be addressed experimentally, imperfect transfection can be516
studied similarly.517
3.2.1. Test for segregation in setup I518
As demonstrated in [62] binding assays in setup I (mixing V1V2 deleted,519
antibody binding resistant envelope proteins with V1V2 expressing, anti-520
body sensitive envelope proteins) lead to a hump-shaped curve for the nor-521
malized mean fluorescence intensity. This result is only in accordance with522
our model predictions for the neighboring protection scenario in which only523
heterotrimers can be bound by one antibody. According to equation 16, the524
mean number of antibodies per trimer is:525
1− f 3−2ξA − (1− fA)3−2ξ (17)
When mixing the two different envelope proteins in equal amounts, fA equals526
0.5 and equation 17 simplifies to 1 − 0.52−2ξ. If there was segregation, we527
predict lower mean fluorescence intensity of a cell population expressing a528
1:1 mix of the two different envelope proteins in comparison to the mean529
fluorescence intensity of a 100% antibody binding sensitive trimer expressing530
cell line. The higher the segregation parameter is, the lower is the mean531
fluorescence intensity of a mixed trimer expressing cell population (down the532
grey line in figure 8). Therefore, the factor with which the mean fluorescence533
intensity of a 100% antibody binding sensitive cell population is higher than534
the mean fluorescence intensity of a mixed envelope trimer expressing pop-535
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ulation increases with increasing segregation parameter ξ. This consequence536
of the mathematical model is shown in Figure 8 C. We experimentally deter-537
mined the mean fluorescence intensity of four independent cell populations538
with a 1:1 ratio of V1V2-deleted, antibody binding resistant envelope pro-539
teins mixed with V1V2-present, antibody binding sensitive envelope proteins.540
Simultaneously with the mixed trimers expressing cell populations, we tested541
a cell population expressing 100% antibody binding sensitive expressing cell542
populations as controls. We find that the mean fluorescence intensity of the543
control populations is on average 2.7 times higher than the mixed trimer544
expressing cell populations (variance of 0.729). This is not as high as the545
predicted factor, which is 4 times higher, but clearly smaller than this fac-546
tor. Only a higher factor is a proof of segregation (see Figure 8 C). This547
strongly suggests that there is no bias towards homotrimers in the mixed548
trimer system employed here. On the basis of a similar calculation this data549
also suggests that there is no imperfect transfection.550
When comparing the effects of imperfect transfection and segregation on551
the predictions for the normalized and the non-normalized mean fluorescence552
intensity, it seems as if both scenarios have the same effect. However, the two553
scenarios are different in terms of the expression level of mixed trimers on554
the cellular surface. In case of complete imperfect transfection (v˜ = 1), each555
cell is transfected with only one type of plasmid and therefore expresses only556
homotrimers of one sort. In the experimental setup I, homotrimers cannot557
be detected by flow cytometry. When the coefficient of variation is slightly558
smaller than one, there are only very few cells transfected with both types of559
plasmids. These cells then express heterotrimers which can be detected by560
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flow cytometry. Hence, in case of imperfect transfection, most of the cells are561
not detected by flow cytometry, because they do not express heterotrimers.562
In contrast, in the segregation model all cells are transfected with a mixture563
of envelope encoding plasmids that represents the experimentally adjusted564
ratios. With increasing segregation parameter, the formation of homotrimers565
becomes more likely. However, a small percentage of the expressed trimers566
are heterotrimers. This leads to a weaker fluorescence signal per cell but567
most of the cells express hetereotrimers. In summary, if the mean fluores-568
cence intensity of cells expressing mixed trimers is much smaller than the569
calculated reduction compared to a 100% sensitive envelope trimer express-570
ing cell, imperfect transfection or segregation could be the explanation. If571
most of the cells cannot be detected in flow cytometry, imperfect transfection572
is the most likeliest explanation for the overall reduction of the mean fluo-573
rescence intensity. If, however, most of the cells show a fluorescence signal,574
segregation is the most likeliest explanation.575
3.3. Defining inter- and intraprotomeric quaternary epitopes of envelope spe-576
cific antibodies577
Neutralizing antibodies which bind to quaternary epitopes have been578
identified in recent years and are of considerable interest due to their po-579
tent and broad activity [19, 60, 76]. In theory, the quaternary epitopes of580
these antibodies can be constituted by components of the same envelope581
protein protomer (non-shared epitope, no cross-linking) or components from582
neighboring protomers within the trimer (shared epitopes, cross linking);583
figure 1B illustrates these two concepts. Walker et al. [76] studied the bind-584
ing of PG9 and PG16 to mixed trimers expressed on cells using a similar585
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approach as presented here. However, in that study, only a 1:2 ratio of wild-586
type to mutant, antibody binding resistant envelope protein was used to test587
for quaternary epitopes. The mean fluorescence intensity of a cell popula-588
tion expressing mixed trimers with the 1:2 envelope ratio was compared to589
the mean fluorescence intensity of a 100% wild-type expressing cell popu-590
lation. With this approach, Walker et al. concluded that PG9 and PG16591
bind to a quaternary structure of the envelope trimer that is not constituted592
by direct inter-protomeric envelope interactions (i.e. non-shared epitopes,593
no cross-linking). In contrast, [27] concluded from electron microscopic re-594
constructions that a single Fab region of PG9 binds asymmetrically to two595
envelope subunits.596
In this section we describe how the binding assay approach for studying597
the mode of V1V2 interaction with V3 can be extended to study inter- and598
intraprotomeric interactions for quaternary epitopes. This approach has the599
advantage that it not only relies on one ratio of wild type and mutant encod-600
ing plasmids, but also on several cell populations expressing different ratios.601
Figure 9 illustrates this concept. Figure 9 A shows a 2-dimensional sketch of602
an antibody binding to an epitope that is only part of one envelope protein603
(non-shared epitope) and of an antibody binding to an epitope consisting of604
two parts that are distributed over two neighboring envelope proteins (shared605
epitopes).606
To study shared/non-shared epitopes, binding assays with cells expressing607
mixed envelope trimers in combination with our model framework can be608
used. The two envelope proteins being employed in these experiments are (i)609
wild-type envelope protein to which the antibody can bind (ii) an envelope610
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mutant with mutations in the epitope regions making the protein antibody611
binding resistant (Figure 9 A). As described above, four different types of612
mixed trimers will be generated when plasmids encoding for the two different613
envelope proteins are co-expressed in a transfected cell. For the binding assay,614
fluorescently labeled antibodies bind to the functional epitopes. If the epitope615
is part of only one envelope protomer, the number of antibodies that can bind616
to one trimer is equal to the number of wild-type envelope proteins in this617
trimer. On the other hand, under the assumption that there is no steric618
hindrance, three antibodies bind to trimers with three wild-type envelope619
proteins, one antibody binds to trimers with two wild-type envelope proteins620
and 0 antibodies to the other trimers if the epitope is shared between two621
envelope proteins (Figure 9 B).622
In equation 4, we derived the normalized mean fluorescence intensity for623
perfectly random trimer assembly which can be used to predict the nor-624
malized mean fluorescence intensity for the shared and non-shared epitope625
hypothesis. According to the trimer table in figure 9, the number of anti-626
bodies binding to the different trimers for the non-shared scenario and the627
shared scenario are n1 = (3, 2, 1, 0) and n2 = (3, 1, 0, 0), respectively. fA is628
the fraction of antibody binding resistant envelope proteins. The predicted629
normalized mean fluorescence intensity, nMFI, for both scenarios are shown630
in Figure 9 (C). If the epitope is located on only one envelope protein, we631
predict a straight line for the nMFI as a function of the fraction of mutant632
envelope proteins. In the case that the epitope is formed from components633
belonging to two envelope protomers, we predict a bow-shaped curve. The634
two curves are clearly distinguishable. It is therefore possible to determine635
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whether an epitope is located on only one envelope protein or shared between636
two envelope proteins within the trimer.637
3.3.1. Advantages and disadvantages of binding and infectivity assays638
In this section we discuss the advantages and disadvantages of binding639
and infectivity assays (additionally summarized in table 2).640
Binding assays. In general, binding assays are useful when studying the num-641
ber of antibodies bound to trimers. The assays average over a high number642
of trimers, and can be applied to determine the modes of shielding epitopes643
from antibody binding or the composition of quaternary epitopes. As, in this644
assay, trimer functionality is measured when trimers are expressed on the cell645
surface, questions related to the role of trimers in the infection process can-646
not be addressed. Therefore, stoichiometric questions related to the infection647
process cannot be studied by binding assays. The analysis of binding assays648
can be confounded by segregation and imperfect transfection but these ef-649
fects can be accounted for with the mathematical model described above.650
Different trimer expression levels are only reflected in the non-normalized651
mean fluorescence intensity but not in the nMFI. If partially shed trimers652
are expressed on the cell surface, which are known to be more accessible to653
antibody binding, the models for binding experiments must be adapted as654
shown in [62]. If antibodies can additionally bind unspecifically, the back-655
ground signal will be higher but will not influence the overall patterns for656
the nMFI of differently mixed trimers.657
Infectivity assays. In general, infectivity assays are of great importance when658
the function of trimers in the infection process is studied, e.g. in determining659
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stoichiometries. However, when using these assays to infer the mode of pro-660
tection from antibody binding conferred by the V1V2 loop, or the location of661
quaternary epitopes in infectivity studies additional knowledge is required.662
In particular, information about the number of trimers is needed for cell entry663
(stoichiometry of entry) and the number of antibodies required to neutralize664
a single trimer (stoichiometry of trimer neutralization) is essential.665
As for binding assays, potential segregation and imperfect transfection666
constitute confounding factors, for which the mathematical analysis can cor-667
rect. In contrary to binding assays, the positions of trimers on the virion668
might also play an important role in infection (see [43, 45]). In these studies669
we also extended the model for infectivity assays to account for a potential670
soft threshold of infection, in which the virion’s ability to infect a target cell671
linearly increases with the number of trimers expressed on its surface. Be-672
cause this soft threshold only plays a role in infection, we do not need to673
consider these potential confounding factors in binding assays.674
Another important issue is that homotrimers of the two envelope vari-675
ants used can have different expression levels, infectivities or stoichiometries676
of entry [6, 72, 73, 85]. This problem can be dealt with by either choosing677
envelope variants with similar features, or by adapting the models to account678
for this variation. Considering all these additional potential confounding fac-679
tors, we suggest to use binding assays whenever determination of infectivity680
is not absolutely required.681
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4. Discussion682
In this paper, we show how mathematical models can help to study the683
molecular interactions between the HIV envelope trimer and antibodies in the684
process of antibody binding and neutralization. As an example, we present685
a detailed model framework that allows the analysis of experimental data686
aimed at investigating the mode of interaction between the V1V2 and V3687
loops within the HIV envelope trimer. In addition, this framework is ex-688
tended to study the protomeric contributions to quaternary epitopes. We689
report here how such mathematical analyses of infectivity and binding as-690
says can fill a methodological gap and reveal molecular aspects that evade691
direct observation by classical approaches such as crystallography or cryo-692
electron microscopy. In addition to providing a way to analyze experimental693
data after their generation, the mathematical models presented here allow694
us to identify the experimental approaches and the envelope mutants that695
are most promising to infer trimeric and protomeric functions for a more696
meaningful experimental design.697
Mixed trimers either expressed on cells [62, 76] or on pseudotyped viruses698
[22, 40, 67, 86–88] form the basis of an experimental approach that can be699
applied to study various functions of the trimer in the entry process and its700
interaction with antibodies. Envelope-expressing cells can be saturated with701
fluorescently marked antibodies and antibody binding to the trimer can be702
tested with flow cytometry. If viruses are studied, they must be saturated703
with antibodies and then tested in infectivity assays. The most important704
twist of the infectivity and binding assays used for this purpose is the combi-705
nation of different envelope proteins with different phenotypic characteristics,706
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for example absence/presence of the V1V2 loop or resistance/sensitivity to707
antibody binding.708
For HIV, it has been shown that antibody binding to the spike is neces-709
sary and sufficient for neutralization [57, 65, 89]. Thus, antibody binding to710
the spike negatively correlates with the infectivity of a virus population. To711
understand how virions evade neutralization by antibodies might not require712
to study the whole infection process. In particular, the mode of protection713
by V1V2 and the formation of quaternary epitopes can be studied with the714
binding assay approach, because these processes only involve scoring of anti-715
body binding and not the infection process. In binding assays it is possible to716
determine the number of antibodies bound to proteins expressed on the cell717
surface measuring the fluorescence intensity. This quantity is proportional718
to the number of intact binding sites. Since the number of trimers expressed719
on a single cell is unknown, the fluorescence signal cannot be directly trans-720
lated into the number of antibodies bound to a single trimer. However, the721
change in the fluorescence intensity for different cell populations can be used722
for inference. This antibody binding based approach informs about the in-723
teraction between antibodies and the trimers. Dependent on the envelope724
variants used, different questions concerning the antibody/trimer interaction725
can be studied. Additionally the binding assay approach circumvents the726
uncertainties surrounding the infection process, namely quantitative infor-727
mation on the trimer number distribution, the stoichiometry of entry, T , and728
the stoichiometry of neutralization, N . However, with this approach it is not729
possible to study how the role of the trimer in the infection process changes730
upon antibody binding.731
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In contrast, approaches relying on infectivity assays have to face these732
uncertainties. The relative infectivity measured in such assays sensitively733
depends on the trimer number distribution and the stoichiometric parame-734
ters. Until now all efforts to estimate these parameters have been inconclusive735
[28, 43, 45, 67, 86, 87, 91], mostly because relative infectivity measures pro-736
vide only limited, macroscopic information that is consistent with a multitude737
of assumptions about the molecular processes underlying neutralization and738
infection. On the other hand, infectivity assays recapitulate a larger part of739
the relevant viral life-cycle. Therefore, all questions related to the infectivity740
of viruses, e.g. the change of infectivity due to antibody binding, can be ad-741
dressed with infectivity assays. We list the advantages and disadvantages of742
binding assays and infectivity assays and the questions that can be addressed743
with either approach in table 2.744
While the binding assay approach circumvents uncertainties about pa-745
rameters only needed in modeling the infection process, we still need to746
make assumptions about the molecular processes of envelope protein expres-747
sion and trimer formation. In our model, we assume that enough plasmids748
enter transfectable cells to guarantee that the translated envelope proteins in749
the transfectable cells represent the mixture of plasmids at the beginning of750
the experiment. In the imperfect transfection model, we relax this assump-751
tion [43, 45]. Furthermore, we assume that trimers form randomly according752
to a binomial distribution from the envelope protein pool within transfected753
cells. In the segregation model we allow a bias towards homotrimer formation754
[43, 45]. These model extensions also predict hump-shaped curves for the nor-755
malized mean fluorescence intensity, nMFI, in binding assays with ∆V1V2,756
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antibody resistant envelope proteins and V1V2 expressing, antibody sensi-757
tive envelope proteins (setup I in figure 4). However, the fluorescence signal758
of the (non-normalized) mean fluorescence intensity for high segregation co-759
efficients or coefficients of variance would be very small in comparison to the760
fluorescence signal of a 100% antibody binding sensitive cell population. Ac-761
cording to our experimental data on the (non-normalized) mean fluorescence762
intensity we conclude that segregation as well as imperfect transfection are763
unlikely to occur in the system studied here.764
Additional support for low segregation as well as imperfect transfection765
coefficients arise from studying the normalized mean fluorescence intensity for766
V1V2 deleted and antibody binding sensitive envelope proteins co-expressed767
with V1V2 present and antibody binding resistant envelope proteins (setup768
II in figure 4 and 5, [62]). In this setup, imperfect transfection would not769
change the predictions for the normalized mean fluorescence intensity. How-770
ever, a high segregation coefficient would straighten the nMFI curve for the771
neighboring scenario. The data in [62] for this setup clearly shows a bow-772
shaped curve, and we therefore conclude that a high segregation coefficient,773
i.e. preferential formation of homo-trimers is unlikely. This conclusion is in774
apparent contradiction with our earlier findings in [45]. In that study, we775
re-analysed a data set by Yang et al. [87] to determine the stoichiometry of776
entry. When applying the segregation model, we estimated a high segrega-777
tion coefficient. However, in the earlier study, a high segregation coefficient778
was only one of many ways to improve the fit of our models to the relative779
infectivity data. Other effects, such as proximity requirements of spikes for780
infection or soft thresholds, could also improve the model fit. Hence, we had781
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cautioned that the improvement of the model fits cannot be interpreted as782
evidence for any of these effects [45]. Besides theoretical caveats concerning783
the different estimates of the segregation coefficient, it might also be possible784
that different envelope variants used have different segregation behaviors.785
In the recent literature several studies can be found which utilized the786
mixed trimer approach to investigate V1V2 loop interactions and quater-787
nary epitopes. [40] studied V1V2 and V3 interactions with infectivity assays788
in a complementation system. The authors concluded that V1V2 interacts789
with the V3 loop of the same envelope protomer (self/cis protection). This790
study did not include mathematical modeling and did not consider that the791
stoichiometry of entry and neutralization can have a huge impact on the va-792
lidity of the interpretation. [76] studied the number of subunits to which one793
monoclonal antibody - either PG9 or PG16 binds. The mean fluorescence794
intensity of one cell population expressing mixed trimers generated with a 1:1795
ratio of wild-type and mutant envelope proteins was used to conclude that796
the quaternary epitopes of PG6 and PG19 are located on one protomer (non-797
shared epitope). This finding was supported by another approach where the798
neutralization potency of antibodies was tested for a number of pseudotyped799
virion populations expressing mixed trimers [13]. The latter study employed800
a best-fit approach without a conceptual mathematical model. However,801
[27] deduced that only a single PG9 binds to the whole trimer by asym-802
metrical interaction of one Fab region with two of the three protomers. In803
the present study, we derived another approach based on binding assays with804
mixed trimers to study the location of a quaternary epitope within the trimer.805
Overall, these approaches require a thorough mathematical analysis based on806
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models including a number of factors that can bias these type of analyses.807
Therefore we see a need for a more detailed assessment and verification of808
confounding factors in these type of studies.809
A precise understanding of the architecture of the viral spike is urgently810
needed to rationally design vaccine immunogens that elicit potent neutraliz-811
ing antibodies. While crystal structures of truncated envelope proteins and812
envelope proteins in complex with CD4 or antibodies as well as cryo-EM813
studies derived over recent years [24, 33, 39, 47, 79] have shed light on the814
molecular architecture of the HIV envelope proteins, much of the molecular815
details remain unknown. For instance, as outlined above, we still lack a de-816
tailed understanding of how precisely the protomers of gp120 interact within817
the trimer. In the intact trimer, some receptor binding sites are shielded818
both by glycan side chains and the variable loops V1V2. The latter potently819
protects the V3 loop within gp120. How precisely the V1V2 domain induces820
shielding has been elusive for a long time as both protection of the V3 loop821
by a neighboring V1V2 domain, or the V1V2 domain from the own protomer822
is conceivable. Identifying the position of V1V2 within the trimer remains823
of high interest as the V1V2 shielding is one of the most powerful protection824
mechanisms against neutralizing antibody attack the virus has evolved. Any825
successful neutralizing antibody regimen, be it prophylactic or therapeutic,826
will need to bypass this shield or as exemplified by the broadly neutralizing827
mAbs identified of late [76], utilize components of the V1V2 in binding to828
the trimer. Defining the precise position and structure of the V1V2 domain829
within the trimer is thus of outmost importance. We believe that a com-830
bination of experimental approaches and mathematical models as outlined831
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here, will shed light on these mechanisms. Our suggested framework is one832
step into this direction which we hope will be followed by further studies833
combining theory with experiments.834
5. Acknowledgements835
We gratefully acknowledge the Swiss National Science Foundation (SNF)836
and the Deutsche Forschungsgemeinschaft (DFG) for funding (CM: PBEZP3 137298837
(SNF) and MA 5320/1-1 (DFG), AT: 310000-120739 (SNF), RRR: 315230-838
13085 (SNF)).839
38
References840
References841
[1] Bar, K. J., Tsao, C. Y., Iyer, S. S., Decker, J. M., Yang, Y., Bonsignori,842
M., Chen, X., Hwang, K. K., Montefiori, D. C., Liao, H. X., Hraber, P.,843
Fischer, W., Li, H., Wang, S., Sterrett, S., Keele, B. F., Ganusov, V. V.,844
Perelson, A. S., Korber, B. T., Georgiev, I., McLellan, J. S., Pavlicek,845
J. W., Gao, F., Haynes, B. F., Hahn, B. H., Kwong, P. D., Shaw, G. M.,846
2012. Early low-titer neutralizing antibodies impede HIV-1 replication847
and select for virus escape. PLoS Pathog 8 (5), e1002721.848
[2] Bunnik, E. M., Euler, Z., Welkers, M. R. A., Boeser-Nunnink, B. D. M.,849
Grijsen, M. L., Prins, J. M., Schuitemaker, H., Aug. 2010. Adaptation850
of HIV-1 envelope gp120 to humoral immunity at a population level.851
Nat Med 16 (9), 991–993.852
[3] Burton, D. R., Ahmed, R., Barouch, D. H., Butera, S. T., Crotty, S.,853
Godzik, A., Kaufmann, D. E., McElrath, M. J., Nussenzweig, M. C.,854
Pulendran, B., Scanlan, C. N., Schief, W. R., Silvestri, G., Streeck, H.,855
Walker, B. D., Walker, L. M., Ward, A. B., Wilson, I. A., Wyatt, R.,856
2012. A Blueprint for HIV Vaccine Discovery. Cell Host Microbe 12 (4),857
396–407.858
[4] Burton, D. R., Poignard, P., Stanfield, R. L., Wilson, I. A., 2012.859
Broadly neutralizing antibodies present new prospects to counter highly860
antigenically diverse viruses. Science 337 (6091), 183–6.861
39
[5] Burton, D. R., Stanfield, R. L., Wilson, I. A., 2005. Antibody vs. HIV862
in a clash of evolutionary titans. Proc Natl Acad Sci USA 102 (42),863
14943–8.864
[6] Cao, J., Sullivan, N., Desjardin, E., Parolin, C., Robinson, J., Wyatt,865
R., Sodroski, J., 1997. Replication and neutralization of human immun-866
odeficiency virus type 1 lacking the V1 and V2 variable loops of the867
gp120 envelope glycoprotein. J Virol 71 (12), 9808–12.868
[7] Chackerian, B., Rudensey, L., Overbaugh, J., OCT 1997. Specific N-869
linked and O-linked glycosylation modifications in the envelope V1 do-870
main of simian immunodeficiency virus variants that evolve in the host871
alter recognition by neutralizing antibodies. J Virol 71 (10), 7719–7727.872
[8] Chen, L., Kwon, Y. D., Zhou, T., Wu, X., O’Dell, S., Cavacini, L.,873
Hessell, A. J., Pancera, M., Tang, M., Xu, L., Yang, Z. Y., Zhang,874
M. Y., Arthos, J., Burton, D. R., Dimitrov, D. S., Nabel, G. J., Posner,875
M. R., Sodroski, J., Wyatt, R., Mascola, J. R., Kwong, P. D., 2009.876
Structural basis of immune evasion at the site of CD4 attachment on877
HIV-1 gp120. Science 326 (5956), 1123–7.878
[9] Chohan, B., Lang, D., Sagar, M., Korber, B., Lavreys, L., Richardson,879
B., Overbaugh, J., MAY 2005. Selection for human immunodeficiency880
virus type I envelope glycosylation variants with shorter V1-V2 loop881
sequences occurs during transmission of certain genetic subtypes and882
may impact viral RNA levels. J Virol 79 (10), 6528–6531.883
[10] Curlin, M. E., Zioni, R., Hawes, S. E., Liu, Y., Deng, W., Gottlieb,884
40
G. S., Zhu, T., Mullins, J. I., 2010. HIV-1 envelope subregion length885
variation during disease progression. PLoS Pathog 6 (12), e1001228.886
[11] Derdeyn, C. A., Decker, J. M., Bibollet-Ruche, F., Mokili, J. L., Mul-887
doon, M., Denham, S. A., Heil, M. L., Kasolo, F., Musonda, R., Hahn,888
B. H., Shaw, G. M., Korber, B. T., Allen, S., Hunter, E., 2004. Envelope-889
constrained neutralization-sensitive HIV-1 after heterosexual transmis-890
sion. Science 303 (5666), 2019–22.891
[12] Doms, R. W., Earl, P. L., Chakrabarti, S., Moss, B., July 1990. Hu-892
man immunodeficiency virus types 1 and 2 and simian immunodeficiency893
virus env proteins possess a functionally conserved assembly domain. J894
Virol 64 (7), 3537–3540.895
[13] Doores, K. J., Burton, D. R., Oct. 2010. Variable Loop Glycan Depen-896
dency of the Broad and Potent HIV-1-Neutralizing Antibodies PG9 and897
PG16. Journal Of Virology 84 (20), 10510–10521.898
[14] Doria-Rose, N. A., Georgiev, I., O’Dell, S., Chuang, G. Y., Staupe, R. P.,899
McLellan, J. S., Gorman, J., Pancera, M., Bonsignori, M., Haynes, B. F.,900
Burton, D. R., Koff, W. C., Kwong, P. D., Mascola, J. R., 2012. A Short901
Segment of the HIV-1 gp120 V1/V2 Region Is a Major Determinant of902
Resistance to V1/V2 Neutralizing Antibodies. J Virol 86 (15), 8319–23.903
[15] Doria-Rose, N. A., Klein, R. M., Daniels, M. G., O’Dell, S., Nason, M.,904
Lapedes, A., Bhattacharya, T., Migueles, S. A., Wyatt, R. T., Korber,905
B. T., Mascola, J. R., Connors, M., 2010. Breadth of human immunod-906
41
eficiency virus-specific neutralizing activity in sera: clustering analysis907
and association with clinical variables. J Virol 84 (3), 1631–6.908
[16] Fox, D., Balfe, P., Palmer, C., May, J., Arnold, C., McKeating, J.,909
JAN 1997. Length polymorphism within the second variable region of910
the human immunodeficiency virus type 1 envelope glycoprotein affects911
accessibility of the receptor binding site. J Virol 71 (1), 759–765.912
[17] Gallo, S. A., Finnegan, C. M., Viard, M., Raviv, Y., Dimitrov, A.,913
Rawat, S. S., Puri, A., Durell, S., Blumenthal, R., 2003. The HIV Env-914
mediated fusion reaction. Biochim Biophys Acta 1614 (1), 36–50.915
[18] Goo, L., Milligan, C., Simonich, C. A., Nduati, R., Overbaugh, J., 2012.916
Neutralizing Antibody Escape during HIV-1 Mother-to-Child Transmis-917
sion Involves Conformational Masking of Distal Epitopes in Envelope.918
J Virol 86 (18), 9566–82.919
[19] Gorny, M. K., Stamatatos, L., Volsky, B., Revesz, K., Williams, C.,920
Wang, X. H., Cohen, S., Staudinger, R., Zolla-Pazner, S., Mar. 2005.921
Identification of a New Quaternary Neutralizing Epitope on Human Im-922
munodeficiency Virus Type 1 Virus Particles. J Virol 79 (8), 5232–5237.923
[20] Groenink, M., Fouchier, R. A., Broersen, S., Baker, C. H., Koot, M.,924
van’t Wout, A. B., Huisman, H. G., Miedema, F., Tersmette, M.,925
Schuitemaker, H., 1993. Relation of phenotype evolution of HIV-1 to926
envelope V2 configuration. Science 260 (5113), 1513–6.927
[21] Harrington, P. R., Nelson, J. A. E., Kitrinos, K. M., Swanstrom, R.,928
MAY 2007. Independent evolution of human immunodeficiency virus929
42
type 1 env V1/V2 and V4/V5 hypervariable regions during chronic in-930
fection. J Virol 81 (10), 5413–5417.931
[22] Herrera, C., Klasse, P. J., Kibler, C. W., Michael, E., Moore, J. P.,932
Beddows, S., 2006. Dominant-negative effect of hetero-oligomerization933
on the function of the human immunodeficiency virus type 1 envelope934
glycoprotein complex. Virology 351 (1), 121–32.935
[23] Hoxie, J. A., 2010. Toward an antibody-based HIV-1 vaccine. Annu Rev936
Med 61, 135–52.937
[24] Hu, G., Liu, J., Taylor, K. A., Roux, K. H., 2011. Structural comparison938
of HIV-1 envelope spikes with and without the V1/V2 loop. J Virol939
85 (6), 2741–50.940
[25] Hughes, E. S., Bell, J. E., Simmonds, P., 1997. Investigation of pop-941
ulation diversity of human immunodeficiency virus type 1 in vivo by942
nucleotide sequencing and length polymorphism analysis of the V1/V2943
hypervariable region of env. J Gen Virol 78 (Pt 11), 2871–82.944
[26] Johnson, W. E., Morgan, J., Reitter, J., Puffer, B. A., Czajak, S., Doms,945
R. W., Desrosiers, R. C., 2002. A replication-competent, neutralization-946
sensitive variant of simian immunodeficiency virus lacking 100 amino947
acids of envelope. J Virol 76 (5), 2075–86.948
[27] Julien, J.-P., Lee, J. H., Cupo, A., Murin, C. D., Derking, R., Hoffen-949
berg, S., Caulfield, M. J., King, C. R., Marozsan, A. J., Klasse, P. J.,950
Sanders, R. W., Moore, J. P., Wilson, I. A., Ward, A. B., Feb. 2013.951
43
Asymmetric recognition of the HIV-1 trimer by broadly neutralizing an-952
tibody PG9. Proceedings Of The National Academy Of Sciences Of The953
United States Of America.954
[28] Klasse, P. J., 2007. Modeling how many envelope glycoprotein trimers955
per virion participate in human immunodeficiency virus infectivity and956
its neutralization by antibody. Virology 369 (2), 245–262.957
[29] Klasse, P. J., Sattentau, Q. J., 2002. Occupancy and mechanism in958
antibody-mediated neutralization of animal viruses. J Gen Virol 83 (Pt959
9), 2091–108.960
[30] Koito, A., Harrowe, G., Levy, J. A., Cheng-Mayer, C., 1994. Functional961
role of the V1/V2 region of human immunodeficiency virus type 1 enve-962
lope glycoprotein gp120 in infection of primary macrophages and soluble963
CD4 neutralization. J Virol 68 (4), 2253–9.964
[31] Kolchinsky, P., Kiprilov, E., Bartley, P., Rubinstein, R., Sodroski, J.,965
2001. Loss of a single N-linked glycan allows CD4-independent human966
immunodeficiency virus type 1 infection by altering the position of the967
gp120 V1/V2 variable loops. J Virol 75 (7), 3435–43.968
[32] Krachmarov, C., Pinter, A., Honnen, W. J., Gorny, M. K., Nyambi,969
P. N., Zolla-Pazner, S., Kayman, S. C., 2005. Antibodies That Are970
Cross-Reactive for Human Immunodeficiency Virus Type 1 Clade A and971
Clade B V3 Domains Are Common in Patient Sera from Cameroon, but972
Their Neutralization Activity Is Usually Restricted by Epitope Masking.973
J Virol 79 (2), 780–90.974
44
[33] Kwon, Y. D., Finzi, A., Wu, X., Dogo-Isonagie, C., Lee, L. K., Moore,975
L. R., Schmidt, S. D., Stuckey, J., Yang, Y., Zhou, T., Zhu, J., Vi-976
cic, D. A., Debnath, A. K., Shapiro, L., Bewley, C. A., Mascola, J. R.,977
Sodroski, J. G., Kwong, P. D., 2012. Unliganded HIV-1 gp120 core struc-978
tures assume the CD4-bound conformation with regulation by quater-979
nary interactions and variable loops. Proc Natl Acad Sci USA.980
[34] Kwong, P. D., Doyle, M. L., Casper, D. J., Cicala, C., Leavitt, S. A., Ma-981
jeed, S., Steenbeke, T. D., Venturi, M., Chaiken, I., Fung, M., Katinger,982
H., Parren, P. W., Robinson, J., Van Ryk, D., Wang, L., Burton, D. R.,983
Freire, E., Wyatt, R., Sodroski, J., Hendrickson, W. A., Arthos, J., 2002.984
HIV-1 evades antibody-mediated neutralization through conformational985
masking of receptor-binding sites. Nature 420 (6916), 678–82.986
[35] Kwong, P. D., Mascola, J. R., 2012. Human Antibodies that Neutral-987
ize HIV-1: Identification, Structures, and B Cell Ontogenies. Immunity988
37 (3), 412–25.989
[36] Labrijn, A. F., Poignard, P., Raja, A., Zwick, M. B., Delgado, K., Franti,990
M., Binley, J., Vivona, V., Grundner, C., Huang, C. C., Venturi, M.,991
Petropoulos, C. J., Wrin, T., Dimitrov, D. S., Robinson, J., Kwong,992
P. D., Wyatt, R. T., Sodroski, J., Burton, D. R., 2003. Access of anti-993
body molecules to the conserved coreceptor binding site on glycoprotein994
gp120 is sterically restricted on primary human immunodeficiency virus995
type 1. J Virol 77 (19), 10557–65.996
[37] Lamers, S. L., Sleasman, J. W., She, J. X., Barrie, K. A., Pomeroy,997
S. M., Barrett, D. J., Goodenow, M. M., 1993. Independent variation998
45
and positive selection in env V1 and V2 domains within maternal-infant999
strains of human immunodeficiency virus type 1 in vivo. J Virol 67 (7),1000
3951–60.1001
[38] Li, Y., Cleveland, B., Klots, I., Travis, B., Richardson, B. A., Anderson,1002
D., Montefiori, D., Polacino, P., Hu, S. L., 2008. Removal of a single1003
N-linked glycan in human immunodeficiency virus type 1 gp120 results1004
in an enhanced ability to induce neutralizing antibody responses. J Virol1005
82 (2), 638–51.1006
[39] Liu, J., Bartesaghi, A., Borgnia, M. J., Sapiro, G., Subramaniam, S.,1007
Jan 2008. Molecular architecture of native HIV-1 gp120 trimers. Nature1008
455 (7209), 109–U76.1009
[40] Liu, L., Cimbro, R., Lusso, P., Berger, E. A., Dec. 2011. Intraprotomer1010
masking of third variable loop (V3) epitopes by the first and second1011
variable loops (V1V2) within the native HIV-1 envelope glycoprotein1012
trimer. Proc Natl Acad Sci USA 108 (50), 20148–20153.1013
[41] Losman, B., Bolmstedt, A., Schonning, K., Bjorndal, A., Westin, C.,1014
Fenyo, E. M., Olofsson, S., 2001. Protection of neutralization epitopes1015
in the V3 loop of oligomeric human immunodeficiency virus type 1 gly-1016
coprotein 120 by N-linked oligosaccharides in the V1 region. AIDS Res1017
Hum Retroviruses 17 (11), 1067–76.1018
[42] Ly, A., Stamatatos, L., 2000. V2 loop glycosylation of the human im-1019
munodeficiency virus type 1 SF162 envelope facilitates interaction of1020
this protein with CD4 and CCR5 receptors and protects the virus from1021
46
neutralization by anti-V3 loop and anti-CD4 binding site antibodies. J1022
Virol 74 (15), 6769–76.1023
[43] Magnus, C., Regoes, R. R., 2010. Estimating the stoichiometry of HIV1024
neutralization. PLoS Comput Biol 6 (3), e1000713.1025
[44] Magnus, C., Regoes, R. R., 2012. Analysis of the Subunit Stoichiometries1026
in Viral Entry. PLoS ONE 7 (3), e33441.1027
[45] Magnus, C., Rusert, P., Bonhoeffer, S., Trkola, A., Regoes, R. R., Feb1028
1 2009. Estimating the stoichiometry of human immunodeficiency virus1029
entry. J Virol 83 (3), 1523–1531.1030
[46] Mao, Y., Wang, L., Gu, C., Herschhorn, A., De´sormeaux, A., Finzi,1031
A., Xiang, S.-H., Sodroski, J. G., 2013. Molecular architecture of the1032
uncleaved HIV-1 envelope glycoprotein trimer. Proceedings Of The Na-1033
tional Academy Of Sciences Of The United States Of America.1034
[47] Mao, Y., Wang, L., Gu, C., Herschhorn, A., Xiang, S. H., Haim, H.,1035
Yang, X., Sodroski, J., 2012. Subunit organization of the membrane-1036
bound HIV-1 envelope glycoprotein trimer. Nat Struct Mol Biol.1037
[48] Mascola, J. R., Montefiori, D. C., 2010. The role of antibodies in HIV1038
vaccines. Annu Rev Immunol 28, 413–44.1039
[49] McLellan, J. S., Pancera, M., Carrico, C., Gorman, J., Julien, J.-P.,1040
Khayat, R., Louder, R., Pejchal, R., Sastry, M., Dai, K., O’Dell, S., Pa-1041
tel, N., Shahzad-Ul-Hussan, S., Yang, Y., Zhang, B., Zhou, T., Zhu, J.,1042
Boyington, J. C., Chuang, G.-Y., Diwanji, D., Georgiev, I., Do Kwon,1043
47
Y., Lee, D., Louder, M. K., Moquin, S., Schmidt, S. D., Yang, Z.-Y.,1044
Bonsignori, M., Crump, J. A., Kapiga, S. H., Sam, N. E., Haynes, B. F.,1045
Burton, D. R., Koff, W. C., Walker, L. M., Phogat, S., Wyatt, R., Or-1046
wenyo, J., Wang, L.-X., Arthos, J., Bewley, C. A., Mascola, J. R., Nabel,1047
G. J., Schief, W. R., Ward, A. B., Wilson, I. A., Kwong, P. D., Apr.1048
2011. Structure of HIV-1 gp120 V1/V2 domain with broadly neutraliz-1049
ing antibody PG9. Nature 480 (7377), 336–343.1050
[50] Montefiori, D. C. D., 2008. Measuring HIV neutralization in a luciferase1051
reporter gene assay. Methods Mol Biol 485, 395–405.1052
[51] Morikita, T., Maeda, Y., Fujii, S., Matsushita, S., Obaru, K., Takatsuki,1053
K., 1997. The V1/V2 region of human immunodeficiency virus type 11054
modulates the sensitivity to neutralization by soluble CD4 and cellular1055
tropism. AIDS Res Hum Retroviruses 13 (15), 1291–9.1056
[52] O’Rourke, S. M., Schweighardt, B., Phung, P., Fonseca, D. P., Terry,1057
K., Wrin, T., Sinangil, F., Berman, P. W., 2010. Mutation at a single1058
position in the V2 domain of the HIV-1 envelope protein confers neu-1059
tralization sensitivity to a highly neutralization-resistant virus. J Virol1060
84 (21), 11200–9.1061
[53] Palmer, C., Balfe, P., Fox, D., May, J., Frederiksson, R., Fenyo, E.,1062
McKeating, J., JUN 15 1996. Functional characterization of the V1V21063
region of human immunodeficiency virus type 1. Virology 220 (2), 436–1064
449.1065
[54] Pastore, C., Nedellec, R., Ramos, A., Pontow, S., Ratner, L., Mosier,1066
48
D. E., 2006. Human immunodeficiency virus type 1 coreceptor switch-1067
ing: V1/V2 gain-of-fitness mutations compensate for V3 loss-of-fitness1068
mutations. J Virol 80 (2), 750–8.1069
[55] Pinter, A., Honnen, W. J., He, Y., Gorny, M. K., Zolla-Pazner, S., Kay-1070
man, S. C., 2004. The V1/V2 domain of gp120 is a global regulator1071
of the sensitivity of primary human immunodeficiency virus type 1 iso-1072
lates to neutralization by antibodies commonly induced upon infection.1073
J Virol 78 (10), 5205–15.1074
[56] Quinones-Kochs, M. I., Buonocore, L., Rose, J. K., 2002. Role of N-1075
linked glycans in a human immunodeficiency virus envelope glycopro-1076
tein: effects on protein function and the neutralizing antibody response.1077
J Virol 76 (9), 4199–211.1078
[57] Ren, X., Sodroski, J., Yang, X., May 2005. An unrelated monoclonal1079
antibody neutralizes human immunodeficiency virus type 1 by binding1080
to an artificial epitope engineered in a functionally neutral region of the1081
viral envelope glycoproteins. J Virol 79 (9), 5616–5624.1082
[58] Ritola, K., Pilcher, C. D., Fiscus, S. A., Hoffman, N. G., Nelson, J. A.,1083
Kitrinos, K. M., Hicks, C. B., Eron, J. J., J., Swanstrom, R., 2004. Mul-1084
tiple V1/V2 env variants are frequently present during primary infection1085
with human immunodeficiency virus type 1. J Virol 78 (20), 11208–18.1086
[59] Robey, W., Safai, B., Oroszlan, S., Arthur, L., Gonda, M., Gallo,1087
R., Fischinger, P., 1985. Characterization of envelope and core struc-1088
49
tural gene-products of HTLV-III with sera from AIDS patients. Science1089
228 (4699), 593–595.1090
[60] Robinson, J. E., Franco, K., Elliott, D. H., Maher, M. J., Reyna,1091
A., Montefiori, D. C., Zolla-Pazner, S., Gorny, M. K., Kraft, Z., Sta-1092
matatos, L., 2010. Quaternary Epitope Specificities of Anti-HIV-1 Neu-1093
tralizing Antibodies Generated in Rhesus Macaques Infected by the1094
Simian/Human Immunodeficiency Virus SHIVSF162P4. J Virol 84 (7),1095
3443–53.1096
[61] Ross, T. M., Cullen, B. R., 1998. The ability of HIV type 1 to use CCR-1097
3 as a coreceptor is controlled by envelope V1/V2 sequences acting in1098
conjunction with a CCR-5 tropic V3 loop. Proc Natl Acad Sci USA1099
95 (13), 7682–6.1100
[62] Rusert, P., Krarup, A., Magnus, C., Brandenberg, O. F., Weber, J.,1101
Ehlert, A.-K., Regoes, R. R., Guenthard, H. F., Trkola, A., Jan 2011.1102
Interaction of the gp120 V1V2 loop with a neighboring gp120 unit shields1103
the HIV envelope trimer against cross-neutralizing antibodies. J Exp1104
Med 208 (7), 1419–1433.1105
[63] Sagar, M., Wu, X., Lee, S., Overbaugh, J., OCT 2006. Human immun-1106
odeficiency virus type 1 V1-V2 envelope loop sequences expand and add1107
glycosylation sites over the course of infection, and these modifications1108
affect antibody neutralization sensitivity. J Virol 80 (19), 9586–9598.1109
[64] Salzwedel, K., Berger, E., Jan 2000. Cooperative subunit interactions1110
within the oligomeric envelope glycoprotein of hiv-1: Functional com-1111
50
plementation of specific defects in gp120 and gp41. Proceedings of the1112
National Academy of Science USA 97 (23), 12794–12799.1113
[65] Sattentau, Q. J., Moore, J. P., 1995. Human immunodeficiency virus1114
type 1 neutralization is determined by epitope exposure on the gp1201115
oligomer. J Exp Med 182 (1), 185–96.1116
[66] Saunders, C. J., McCaffrey, R. A., Zharkikh, I., Kraft, Z., Malenbaum,1117
S. E., Burke, B., Cheng-Mayer, C., Stamatatos, L., 2005. The V1, V2,1118
and V3 regions of the human immunodeficiency virus type 1 envelope1119
differentially affect the viral phenotype in an isolate-dependent manner.1120
J Virol 79 (14), 9069–80.1121
[67] Schonning, K., Lund, O., Lund, O. S., Hansen, J.-E. S., 1999. Stoi-1122
chiometry of monoclonal antibody neutralization of T-cell line-adapted1123
human immunodeficiency virus type 1. J Virol, 8364–8370.1124
[68] Shibata, J., Yoshimura, K., Honda, A., Koito, A., Murakami, T., Mat-1125
sushita, S., 2007. Impact of V2 mutations on escape from a potent1126
neutralizing anti-V3 monoclonal antibody during in vitro selection of1127
a primary human immunodeficiency virus type 1 isolate. J Virol 81 (8),1128
3757–68.1129
[69] Shioda, T., Levy, J. A., Cheng-Mayer, C., 1991. Macrophage and T cell-1130
line tropisms of HIV-1 are determined by specific regions of the envelope1131
gp120 gene. Nature 349 (6305), 167–9.1132
[70] Stamatatos, L., Cheng-Mayer, C., 1998. An envelope modification that1133
renders a primary, neutralization-resistant clade B human immunodefi-1134
51
ciency virus type 1 isolate highly susceptible to neutralization by sera1135
from other clades. J Virol 72 (10), 7840–5.1136
[71] Stamatatos, L., Morris, L., Burton, D. R., Mascola, J. R., 2009. Neutral-1137
izing antibodies generated during natural HIV-1 infection: good news1138
for an HIV-1 vaccine? Nat Med 15 (8), 866–70.1139
[72] Stamatatos, L., Wiskerchen, M., Cheng-Mayer, C., 1998. Effect of major1140
deletions in the V1 and V2 loops of a macrophage-tropic HIV type 11141
isolate on viral envelope structure, cell entry, and replication. AIDS Res1142
Hum Retroviruses 14 (13), 1129–39.1143
[73] Sullivan, N., Thali, M., Furman, C., Ho, D. D., Sodroski, J., 1993. Effect1144
of amino acid changes in the V1/V2 region of the human immunodefi-1145
ciency virus type 1 gp120 glycoprotein on subunit association, syncytium1146
formation, and recognition by a neutralizing antibody. J Virol 67 (6),1147
3674–9.1148
[74] Toohey, K., Wehrly, K., Nishio, J., Perryman, S., Chesebro, B., 1995.1149
Human immunodeficiency virus envelope V1 and V2 regions influence1150
replication efficiency in macrophages by affecting virus spread. Virology1151
213 (1), 70–9.1152
[75] Veronese, F., Devico, A., Copeland, T., Oroszlan, S., Gallo, R., Sarn-1153
gadharan, M., 1985. Characterization of gp41 as the transmembrane1154
protein coded by the HTLV-III/LAV envelope gene. Science 229 (4720),1155
1402–1405.1156
52
[76] Walker, L., Phogat, S., Chan-Hui, P., Wagner, D., Phung, P., Goss,1157
J., Wrin, T., Simek, M., Fling, S., Mitcham, J., Lehrman, J., Priddy,1158
F., Olsen, O., Frey, S., Hammond, P., Kaminsky, S., Zamb, T., Moyle,1159
M., Koff, W., Poignard, P., Burton, D., Jan 2009. Broad and Potent1160
Neutralizing Antibodies from an African Donor Reveal a New HIV-11161
Vaccine Target. Science 326 (5950), 285–289.1162
[77] Wei, X., Decker, J., Wang, S., Hui, H., Kappes, J., Wu, X., Salazar-1163
Gonzalez, J., Salazar, M., Kilby, J., SAAG, M., Komarova, N., Nowak,1164
M., HAHN, B., Kwong, P., SHAW, G., Jan 2003. Antibody neutraliza-1165
tion and escape by HIV-1. Nature 422 (6929), 307–312.1166
[78] Wei, X., Decker, J. M., Liu, H., Zhang, Z., Arani, R. B., Kilby, J. M.,1167
Saag, M. S., Wu, X., Shaw, G. M., Kappes, J. C., 2002. Emergence of1168
Resistant Human Immunodeficiency Virus Type 1 in Patients Receiving1169
Fusion Inhibitor (T-20) Monotherapy. Antimicrob Agents Chemother,1170
1–10.1171
[79] White, T. A., Bartesaghi, A., Borgnia, M. J., Meyerson, J. R., de la1172
Cruz, M. J. V., Bess, J. W., Nandwani, R., Hoxie, J. A., Lifson,1173
J. D., Milne, J. L. S., Subramaniam, S., DEC 2010. Molecular Archi-1174
tectures of Trimeric SIV and HIV-1 Envelope Glycoproteins on Intact1175
Viruses: Strain-Dependent Variation in Quaternary Structure. PLoS1176
Pathog 6 (12).1177
[80] Wilen, C. B., Tilton, J. C., Doms, R. W., 2012. Molecular mechanisms1178
of HIV entry. Adv Exp Med Biol 726, 223–42.1179
53
[81] Wolk, T., Schreiber, M., 2006. N-Glycans in the gp120 V1/V2 domain of1180
the HIV-1 strain NL4-3 are indispensable for viral infectivity and resis-1181
tance against antibody neutralization. Med Microbiol Immunol 195 (3),1182
165–72.1183
[82] Wu, X., Zhou, T., O’Dell, S., Wyatt, R. T., Kwong, P. D., Mascola,1184
J. R., 2009. Mechanism of human immunodeficiency virus type 1 resis-1185
tance to monoclonal antibody B12 that effectively targets the site of1186
CD4 attachment. J Virol 83 (21), 10892–907.1187
[83] Wyatt, R., Moore, J., Accola, M., Desjardin, E., Robinson, J., Sodroski,1188
J., 1995. Involvement of the V1/V2 variable loop structure in the expo-1189
sure of human immunodeficiency virus type 1 gp120 epitopes induced1190
by receptor binding. J Virol 69 (9), 5723–33.1191
[84] Wyatt, R., Sodroski, J., 1998. The HIV-1 envelope glycoproteins: fuso-1192
gens, antigens, and immunogens. Science 280 (5371), 1884–1888.1193
[85] Wyatt, R., Sullivan, N., Thali, M., Repke, H., Ho, D., Robinson, J.,1194
Posner, M., Sodroski, J., 1993. Functional and immunologic characteri-1195
zation of human immunodeficiency virus type 1 envelope glycoproteins1196
containing deletions of the major variable regions. J Virol 67 (8), 4557–1197
65.1198
[86] Yang, X., Kurteva, S., Lee, S., Sodroski, J., 2005. Stoichiometry of1199
antibody neutralization of Human Immunodeficiency Virus type 1. J1200
Virol 79 (6), 3500–8.1201
54
[87] Yang, X., Kurteva, S., Ren, X., Lee, S., Sodroski, J., 2005. Stoichiome-1202
try of envelope glycoprotein trimers in the entry of Human Immunode-1203
ficiency Virus type 1. J Virol 79 (19), 12132–47.1204
[88] Yang, X., Kurteva, S., Ren, X., Lee, S., Sodroski, J., 2006. Subunit1205
stoichiometry of human immunodeficiency virus type 1 envelope glyco-1206
protein trimers during virus entry into host cells. J Virol 80 (9), 4388–95.1207
[89] Yang, X., Lipchina, I., Cocklin, S., Chaiken, I., Sodroski, J., November1208
2006. Antibody binding is a dominant determinant of the efficiency of1209
human immunodeficiency virus type 1 neutralization. J Virol 80 (22),1210
11404–11408.1211
[90] Yang, Z. Y., Chakrabarti, B. K., Xu, L., Welcher, B., Kong, W. P.,1212
Leung, K., Panet, A., Mascola, J. R., Nabel, G. J., 2004. Selective mod-1213
ification of variable loops alters tropism and enhances immunogenicity of1214
human immunodeficiency virus type 1 envelope. J Virol 78 (8), 4029–36.1215
[91] Zhu, P., Liu, J., Bess, Jr, J., Chertova, E., Lifson, J. D., Grise, H.,1216
Ofek, G. A., Taylor, K. A., Roux, K. H., 2006. Distribution and three-1217
dimensional structure of AIDS virus envelope spikes. Nature 441 (7095),1218
847–52.1219
55
Figures1220
A B
3D
 s
ch
em
e
to
p 
vi
ew
mode of V1V2 protection quaternary epitopes
self neighboring shared non-shared
Figure 1: Sketch of the two main research questions addressed here. (A) Does the V1V2
loop protect V3 epitopes by shielding the epitope of the same protomer (self protection) or
a neighboring protomer (neighboring protection)? (B) Does an antibody specific epitope
consist of regions from different protomers (shared epitope) or from only one protomer
(non-shared epitope)? The top row shows three-dimensional schematic representation of
the envelope trimer with blue epitopes, dark grey V1V2 loops and red antibodies. The
bottom row shows a two-dimensional scheme of the envelope protomers depicted as circles.
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Figure 2: Sketch of the different experimental setups. A Transfection of virus producer
cells with two types of plasmids encoding two different envelope protein types. The result-
ing trimer-expressing cells are saturated with fluorescently labeled antibodies and analyzed
with flow cytometry. B To produce pseudotype virus stocks, cells are additionally trans-
fected with plasmids encoding for the genetic information of the virion. The resulting
pseudotype virions are saturated with antibodies and subjected to target cells, followed
by scoring of target cell infection.
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Figure 3: Schematic of a flow cytometry readout with three transfected cell populations.
The grey shaded area represents the background signal of mock-transfected cells with mean
fluorescence intensity mb. The blue and the red curves are the fluorescence signals of two
cell populations expressing different amounts of type 1 and type 2 envelope proteins with
different sensitivities to a fluorescently labeled antibody against the epitope of interest.
Their mean fluorescence intensity, MFI, can be calculated by subtracting the background
mean fluorescence intensity, mb from the mean of the whole curvesm1 andm2, respectively.
This means MFIi = mi −mb for i = 1, 2. For the normalized mean fluorescence intensity,
nMFI, the calculated mean fluorescence intensities have to be divided by the maximum of
the mean fluorescence intensities, i.e. nMFIi = (mi −mb)/max {MFI1,MFI2}.
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Figure 4: Trimer tables for differently mixed trimers (rows, referred to as setups) and
testing experiments (columns, referred to as approaches) to study the mode of protection
the V1V2 loop confers. Red rectangles represent antibody resistant binding sites and
blue rectangles antibody sensitive sites. The grey shapes symbolize the V1V2 loops. In
binding assays, the mean fluorescence intensity is a measure for the number of antibodies
bound to an average trimer. Thus we show all envelope combinations and the number of
antibodies bound in the two different protection modes. In infectivity assays, functional
trimers (marked with a ”+”, non-functional trimers are marked with ”–”) take part in
mediating cell entry. A trimer is functional if less than N antibodies are bound, as defined
by the stoichiometry of trimer neutralization. Parts of this figure are adapted from figures
5, 6 and 7 in [62].
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Figure 5: Predictions of our model for the mode of epitope masking by the V1V2 loop.
This scheme contrasts the predictions of the normalized MFI measured in binding assays
(left column) with the predictions of the relative infectivity in infectivity assays (right
column) for all possible three envelope setups (rows). Predictions for the neighboring
scenario are colored blue, predictions for the self protection scenario are colored green.
Parts of this figure are adapted from figures 5 and 6 in [62].
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Figure 6: Influence of the stoichiometry of entry in infectivity experiments for A setup I
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Figure 7: Influence of A imperfect transfection and B segregation on the predictions of
the normalized mean fluorescence intensity for the experimental setup I in figure 4. Parts
of this figure are adapted from figure S3 in [62].
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Figure 8: The influence of (A) imperfect transfection and (B) potential segregation on the
mean fluorescence intensity for cell populations expressing mixed trimers of V1V2 deleted,
antibody binding resistant envelope proteins with V1V2 expressing, antibody sensitive
envelope proteins (setup I). As the signal in setup I comes from heterotrimers and as the
fraction of heterotrimers decreases with increasing imperfect transfection (v˜ → 1) and
segregation (ξ → 1), the maximal value of the mean fluorescence intensity decreases. (C)
The mean fluorescence intensity of a 100% antibody binding sensitive cell population,
MFIabs divided by the mean fluorescence intensity of a cell population transfected with
equal amounts of envelope proteins of the two different types is a measure of how much
the segregation parameter influences the expression of heterotrimers. The higher the
segregation parameter is, the smaller is the mean fluorescence intensity of a cell population
expressing mixed trimers.
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Figure 9: A Sketch of shared epitopes. The black circles represent one envelope protein.
The epitope is marked blue. B Number of antibodies binding to the mixed trimers con-
sisting of envelope proteins with intact epitopes (blue) or mutations making the envelope
antibody binding resistant (red) for the two epitope scenarios shared (green shaded table)
and non-shared (blue shaded table). C Theoretical predictions for the normalized mean
fluorescence intensity.
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Table 1: Parameter definitions.
fi fraction of type i envelope proteins in the envelope pool
RI function for the relative infectivity
MFI function for the mean fluorescence intensity
nMFI function for the normalized mean fluorescence intensity
S mode of protection (neighboring or self) or epitope (shared or non-shared)
T stoichiometry of entry, number of trimer cell-receptor interactions required
for infection
N stoichiometry of neutralization, number of antibodies rendering one
trimer non-functional
ηs probability that virion has s trimers
αS,N probability of forming a functional trimer
X number of antibodies bound to one random trimer
n = (n0, n1, n2, n3), vector with number of antibodies bound to trimers with
0,1,2,3 mutant envelope proteins
v˜ coefficient of variation
ξ segregation coefficient
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Table 2: Overview of the properties of the different assays using mixed trimers to resolve
HIV envelope trimer functions.
Binding assay Infectivity assay
Mode of V1V2 protection: Dis-
tinction between inter- and intra-
protomeric interaction
yes only for some setups and sto-
ichiometries, prior knowledge
about stoichiometries necessary
Quaternary epitopes: Distinc-
tion between inter- and intra-
protomeric interaction
yes only for some setups and sto-
ichiometries, prior knowledge
about stoichiometries necessary
Determination of entry stoi-
chiometry [28, 45, 87]
no yes
Determination of stoichiometry
of neutralization [28, 43, 86]
no yes
Determination of subunit
stoichiometries (CD4, corecep-
tor, fusion protein, subunit
cooperation)[44, 88]
no yes
Influenced by trimer segregation yes yes
Influenced by imperfect transfec-
tion
yes yes
Influenced by trimer expression
level on cell/virus surface
only the absolute fluorescence
signal, but not the normalized
mean fluorescence intensity
yes
Influenced by antibodies bind-
ing to monomer or dimer on
cell/virus surface
yes no
Influenced by antibodies binding
to non-functional trimers
yes no
Influenced by different infectivi-
ties/entry stoichiometries of ho-
motrimers of the different enve-
lope proteins used
no yes
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